CL2014003567A1 - Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter. - Google Patents

Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter.

Info

Publication number
CL2014003567A1
CL2014003567A1 CL2014003567A CL2014003567A CL2014003567A1 CL 2014003567 A1 CL2014003567 A1 CL 2014003567A1 CL 2014003567 A CL2014003567 A CL 2014003567A CL 2014003567 A CL2014003567 A CL 2014003567A CL 2014003567 A1 CL2014003567 A1 CL 2014003567A1
Authority
CL
Chile
Prior art keywords
recombinant
composition
sulfatase
formulation
purification method
Prior art date
Application number
CL2014003567A
Other languages
English (en)
Inventor
Dave Nichols
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003567(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of CL2014003567A1 publication Critical patent/CL2014003567A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CL2014003567A 2012-06-29 2014-12-29 Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter. CL2014003567A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
CL2014003567A1 true CL2014003567A1 (es) 2015-04-24

Family

ID=49778401

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003567A CL2014003567A1 (es) 2012-06-29 2014-12-29 Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter.

Country Status (38)

Country Link
US (6) US9051556B2 (es)
EP (2) EP3441398A1 (es)
JP (4) JP6171007B2 (es)
KR (5) KR101380740B1 (es)
CN (3) CN104583225A (es)
AR (1) AR091647A1 (es)
AU (3) AU2013282395C1 (es)
BR (1) BR112014032567B1 (es)
CA (2) CA2877517C (es)
CL (1) CL2014003567A1 (es)
CO (1) CO7240396A2 (es)
CR (1) CR20140588A (es)
CY (1) CY1121519T1 (es)
DK (1) DK2867245T3 (es)
DO (1) DOP2014000294A (es)
EA (2) EA034549B1 (es)
ES (1) ES2689468T3 (es)
GT (1) GT201400303A (es)
HK (4) HK1209431A1 (es)
HR (1) HRP20181897T1 (es)
HU (1) HUE040769T2 (es)
IL (4) IL236315A (es)
LT (1) LT2867245T (es)
MX (3) MX336715B (es)
MY (3) MY180287A (es)
NZ (3) NZ733366A (es)
PE (1) PE20150720A1 (es)
PH (3) PH12014502871A1 (es)
PL (1) PL2867245T3 (es)
PT (1) PT2867245T (es)
RS (1) RS58005B1 (es)
SG (2) SG10201703489VA (es)
SI (1) SI2867245T1 (es)
TR (1) TR201815811T4 (es)
TW (2) TWI587869B (es)
UA (1) UA121959C2 (es)
WO (1) WO2014005014A2 (es)
ZA (2) ZA201409397B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
JP6993814B2 (ja) 2016-08-25 2022-01-14 Ｊｃｒファーマ株式会社 抗体融合蛋白質の製造方法
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
US20220002688A1 (en) * 2018-12-20 2022-01-06 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
AU2021364779A1 (en) * 2020-10-23 2023-06-01 Alexion Pharmaceuticals, Inc. Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
AU700369B2 (en) 1994-03-16 1999-01-07 Regents Of The University Of California, The Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP1179000A4 (en) 1999-02-26 2005-10-12 Millennium Pharm Inc DECISION PROTEINS AND THEIR USE
CA2368797C (en) 1999-04-26 2010-08-17 Genentech, Inc. Cell culture process
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
JP2003508088A (ja) 1999-09-03 2003-03-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５２個のヒト分泌タンパク質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
EP1255819A2 (en) 2000-02-17 2002-11-13 Incyte Genomics, Inc. Human kinases
CA2400638A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
MXPA05006523A (es) * 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
NZ603330A (en) 2003-02-11 2015-02-27 Shire Human Genetic Therapies Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
CN101437839A (zh) 2006-03-20 2009-05-20 米德列斯公司 蛋白质纯化
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
HUE032074T2 (en) 2008-01-18 2017-08-28 Biomarin Pharm Inc Preparation and use of active, highly phosphorylated, human lisosomal sulfatase enzymes
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
KR20230159646A (ko) 2010-06-25 2023-11-21 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
EP2585105B1 (en) * 2010-06-25 2017-08-09 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US9381241B2 (en) * 2010-09-28 2016-07-05 Kyoritsu Seiyaku Corporation Mucosal adjuvant composition
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
US20140022222A1 (en) 2011-01-31 2014-01-23 Huei Pei Kuo Diffuser with a dynamically tunable scattering angle
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
ZA201803289B (en) 2021-04-28
US9051556B2 (en) 2015-06-09
TW201703794A (zh) 2017-02-01
AU2013282395C1 (en) 2016-03-24
HK1209431A1 (en) 2016-04-01
PT2867245T (pt) 2018-11-26
MX366906B (es) 2019-07-30
LT2867245T (lt) 2018-11-12
SG10201703489VA (en) 2017-05-30
MX2015000190A (es) 2015-04-08
MY157087A (en) 2016-04-19
MY180287A (en) 2020-11-27
EA202090044A1 (ru) 2020-07-31
PH12015502408B1 (en) 2018-03-26
BR112014032567B1 (pt) 2022-09-13
BR112014032567A2 (pt) 2017-08-01
TR201815811T4 (tr) 2018-11-21
KR101380740B1 (ko) 2014-04-11
CO7240396A2 (es) 2015-04-17
TW201410868A (zh) 2014-03-16
IL236315A (en) 2016-11-30
TWI587869B (zh) 2017-06-21
WO2014005014A3 (en) 2014-02-27
AU2016200469B2 (en) 2017-10-12
EA034549B1 (ru) 2020-02-19
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
CA2877517C (en) 2018-07-31
JP6505629B2 (ja) 2019-04-24
SI2867245T1 (sl) 2018-12-31
JP2015523072A (ja) 2015-08-13
CN107596357A (zh) 2018-01-19
US20150313972A1 (en) 2015-11-05
MX336715B (es) 2016-01-28
CN107596358A (zh) 2018-01-19
AR091647A1 (es) 2015-02-18
KR20140004603A (ko) 2014-01-13
SG11201408761VA (en) 2015-01-29
EA201492177A1 (ru) 2015-06-30
HK1249026A1 (zh) 2018-10-26
NZ743910A (en) 2019-12-20
WO2014005014A2 (en) 2014-01-03
AU2013282395A1 (en) 2015-01-29
HUE040769T2 (hu) 2019-03-28
IL287057A (en) 2021-12-01
TWI553120B (zh) 2016-10-11
PE20150720A1 (es) 2015-05-16
JP2020105209A (ja) 2020-07-09
CY1121519T1 (el) 2020-05-29
NZ703093A (en) 2017-08-25
IL248727A0 (en) 2017-01-31
PL2867245T3 (pl) 2019-02-28
PH12014502871B1 (en) 2015-02-23
MY192068A (en) 2022-07-25
EP2867245B1 (en) 2018-09-12
NZ733366A (en) 2019-12-20
AU2016200469A1 (en) 2016-02-18
AU2013282395B2 (en) 2015-12-03
KR20140002451A (ko) 2014-01-08
US10344270B2 (en) 2019-07-09
US20240043817A1 (en) 2024-02-08
RS58005B1 (sr) 2019-02-28
EP2867245A4 (en) 2016-03-09
IL236315A0 (en) 2015-02-26
IL261264B (en) 2021-10-31
DK2867245T3 (en) 2018-11-26
US20210317426A1 (en) 2021-10-14
KR20190064542A (ko) 2019-06-10
KR20200143339A (ko) 2020-12-23
AU2018200230B2 (en) 2020-01-02
HRP20181897T1 (hr) 2019-01-11
US11530393B2 (en) 2022-12-20
US9492511B2 (en) 2016-11-15
US20170073652A1 (en) 2017-03-16
US20140004096A1 (en) 2014-01-02
EP3441398A1 (en) 2019-02-13
CA3008945A1 (en) 2014-01-03
JP2016119911A (ja) 2016-07-07
CN104583225A (zh) 2015-04-29
DOP2014000294A (es) 2015-03-15
KR20220002227A (ko) 2022-01-06
ES2689468T3 (es) 2018-11-14
JP6171007B2 (ja) 2017-07-26
ZA201409397B (en) 2019-10-30
JP2018121645A (ja) 2018-08-09
EP2867245A2 (en) 2015-05-06
GT201400303A (es) 2017-08-31
IL261264A (en) 2018-10-31
HK1249027A1 (zh) 2018-10-26
US20190359958A1 (en) 2019-11-28
MX2019008914A (es) 2019-09-26
CA2877517A1 (en) 2014-01-03
AU2018200230A1 (en) 2018-02-01
UA121959C2 (uk) 2020-08-25
PH12014502871A1 (en) 2015-02-23
PH12015502408A1 (en) 2018-03-26
PH12020500027A1 (en) 2021-03-15

Similar Documents

Publication Publication Date Title
CL2014003567A1 (es) Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter.
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
CL2016001166A1 (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia
IL244995B (en) A pharmaceutical composition containing a pcsk9 inhibitor in the treatment of hyperlipidemia
CL2014003357A1 (es) Composición sinérgica para la protección de cultivos agrícolas y su uso
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2013001107A1 (es) Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
DK3329909T3 (da) Fenfluramin til anvendelse i behandling af dravet syndrom
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2014000948A1 (es) Profarmaco de adrenomedulina basado en polietilenglicol; procedimiento de preparacion; composicion farmaceutica que lo comprende; y su uso para tratar y/o prevenir trastornos cardiovasculares, edematosos y/o inflamatorios.
DK2861223T3 (da) Sammensætninger og metoder til transmukosal absorption
BR112014001991A2 (pt) certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos
EP2881112A4 (en) PHARMACEUTICAL COMPOSITION FOR PROMOTING RESTORATION OF NERVE INJURY AND ITS APPLICATION
CL2015000049A1 (es) Método y composición para secuestrar arsénico.
EP3031322A4 (en) Composition comprising harmful arthropod-attracting substance formed from plant-derived components and analogs thereof
BR112014028280A2 (pt) composições farmacêuticas tópicas compreendendo terbinafina e ureia
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112014026357A2 (pt) composição e sistema
BR112015027026A8 (pt) composição para uso na redução da formação de casca e na promoção da cicatrização
BR112015012149A2 (pt) método para a remoção de uma ou mais substâncias químicas de um material de tabaco, material de tabaco, artigo para fumar e uso de um líquido iônico para remover proteínas e/ou polifenóis
BR112015008798A2 (pt) método para o tratamento de plantas e uso